- Home
- LRMR
as 11-06-2025 3:09pm EST
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | BALA CYNWYD |
| Market Cap: | 332.1M | IPO Year: | N/A |
| Target Price: | $16.71 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.95 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.61 - $9.50 | Next Earning Date: | 11-05-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Larimar Therapeutics Inc. News
LRMR Breaking Stock News: Dive into LRMR Ticker-Specific Updates for Smart Investing
Associated Press Finance
a day ago
Larimar: Q3 Earnings Snapshot
GlobeNewswire
a day ago
Larimar Therapeutics Reports Third Quarter 2025 Financial Results
Simply Wall St.
a month ago
Will Positive Nomlabofusp Study Results Alter Larimar Therapeutics' (LRMR) Standing in Rare Disease Treatment?
Zacks
4 months ago
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats
MT Newswires
4 months ago
Larimar Plans to Seek FDA Approval for Nomlabofusp in Q2 2026
GlobeNewswire
4 months ago
Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich’s Ataxia Program
GlobeNewswire
5 months ago
Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia
GOBankingRates
5 months ago
7 Luxury Vehicles Expected To Skyrocket in Price Due To Trump’s Tariffs
Compare LRMR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LRMR Larimar Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.